Venclexta (venetoclax)

pCPA File Number: 21035

Negotiation Status:

Concluded with an LOI

Indication(s):

As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-Cell Receptor Inhibitor (BCRi)

Sponsor/Manufacturer:

AbbVie Corporation

CDA-AMC Project Number:

PC0105-000

pCPA Engagement Letter Issued:

2018-06-21

Negotiation Process Concluded:

2019-03-06